BREAKING NEWS! We have completed dosing in Cohort 5 of our ongoing ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases, with a total of 18 patients have been dosed in the trial to date.
The trial is STILL ENROLLING and accepting new patients, and you can find more information about it on our website at https://www.respect-trials.com/lm/
Press Release: bit.ly/PSTV_PR
#BrainCancer #ClinicalTrials #BreastCancer #LungCancer #Oncology
Recent Comments